Novo Nordisk (NVO) R&D US GAAP (year values) |
|||||||||
2021 | 2021 | 2022 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
R&D | 17 772 000 000 | 17 772 000 000 | 24 047 000 000 | 24 047 000 000 | 32 443 000 000 | 35 232 000 000 | |||
Changes by years, y/y, % | +15% | 0% | +35% | 0% | +35% | +17.0% |
Novo Nordisk. R&D
Novo Nordisk. R&D, changes, %
Novo Nordisk. R&D, sum by quarters
Novo Nordisk (NVO) R&D US GAAP (quarter values) |
||||||||
2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
R&D | 7 127 000 000 | 8 128 000 000 | 10 460 000 000 | 8 606 000 000 | 16 166 000 000 | 35 232 000 000 | ||
Changes by years, y/y, % | +39% | +44% | +29% | +28% | +127% | |||
Changes by quarters, q/q, % | +14% | +29% | -18% | +88% |